Abstract:Abstract: OBJECTIVE To explore the clinical efficacy of hepatic arterial chemoembolization (TACE) combined with apatinib in treating unresectable gastric cancer liver metastasis and its effect on the expression of serum vascular endothelial growth factor (VEGF). METHODS A prospective study was conducted on 120 patients who went to the Oncology Department of Shibei Hospital of Jingan District in Shanghai from July 2020 to December 2021. Among them, 60 patients in the control group were treated with apa⁃ tinib and anti-angiogenic targeting; 60 patients in the observation group were treated with TACE and apatinib, and both groups were continuously treated for 3 months. Serum VEGF concentrations and their clinical efficacy were compared between the two groups. RESULTS After 3 months of treatment, the serum VEGF concentration in the observation group was (126.08 ± 12.35) pg/ml and (181.52±11.7) pg/ml in the control group, with a significant difference (t=25.212, P＜0.05). The overall treatment effect of the pa⁃ tients in the observed group was better than that in the control group, which was statistically significant (χ2 =6.314, P＜0.05). After treatment, the objective response rate and disease control rate were 43.4% and 73.4%, respectively, and 25.0% and 55.0%, respec⁃ tively, which were significant (χ2 =4.483, 4.385, P＜0.05). After treatment, the progression-free survival period was (14.36 ± 1.87) months and patients (10.25±1.45) months, which was significantly significant (t=13.454, P＜0.05). CONCLUSION TACE combined with apatinib in patients with unresectable gastric cancer liver metastasis has better clinical efficacy than apatinib alone, and is bene⁃ ficial to prolong the patient survival cycle.